By Fineline Cube Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that China’s National Medical Products Administration (NMPA) has granted marketing approval for HSK39297, a Category 1 innovative oral small-molecule inhibitor of Complement Factor B (CFB) indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Full marketing approval, Category 1 innovative drug |
| Product | HSK39297 tablets (oral, once daily) |
| Indication | Treatment of adult PNH patients naïve to complement inhibitor therapy |
| Approval Date | 23 Jul 2026 |
| Disclosure Assurance | Company and Board guarantee information accuracy and completeness |
Drug Profile & Mechanism of Action
- Molecule: Highly potent and selective oral small-molecule inhibitor of Complement Factor B (CFB)
- Target: Proximal link of the alternative pathway in the complement cascade
- Innovation: First-in-class therapy enabling “full-chain” intervention against PNH hemolysis by simultaneously inhibiting terminal complement-driven intravascular hemolysis and controlling C3b-mediated extravascular hemolysis
- Therapeutic Effect: Blocks activation of the alternative pathway (AP) and complement amplification loop, suppressing overall complement pathway activity at its source
- Administration: Once-daily oral tablet designed to improve long-term patient compliance
- Development Status: Independently developed by Haisco Pharma with potential applications across various diseases mediated by abnormal complement activation
Market Impact & Outlook
- PNH Treatment Landscape: Current PNH therapies primarily target terminal complement components; HSK39297’s proximal targeting represents a paradigm shift in disease management
- Patient Population: China has an estimated 5,000-8,000 PNH patients, with significant unmet need for oral therapies that address both intravascular and extravascular hemolysis
- Competitive Advantage: As the first oral CFB inhibitor approved in China, HSK39297 offers superior convenience over intravenous alternatives while providing comprehensive hemolysis control
- Commercial Strategy: Haisco plans to leverage its established hospital distribution network to ensure rapid market penetration among hematologists and specialized treatment centers
- Pipeline Potential: The CFB inhibition platform may support expansion into other complement-mediated diseases including atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, clinical outcomes, and commercial expectations for HSK39297. Haisco Pharmaceutical Group Co., Ltd. and all members of the Board of Directors guarantee that the disclosed information is true, accurate, and complete, containing no false records, misleading statements, or material omissions. Actual results may differ due to risks including market adoption, competitive dynamics, and regulatory requirements.-Fineline Info & Tech